Efficacy of a Therapeutic Vaccine Using Mutated β-amyloid Sensitized Dendritic Cells in Alzheimer’s Mice

摘要: Despite FDA suspension of Elan’s AN-1792 amyloid beta (Aβ) vaccine in phase IIb clinical trials, the implications this study are guiding principles for contemporary anti-Aβ immunotherapy against Alzheimer’s disease (AD). showed promising results with regards to Aβ clearance and cognitive function improvement, but also exhibited an increased risk Th1 mediated meningoencephalitis. As such, development has continued emphasis on eliciting a notable antibody titer, while avoiding unwanted pro-inflammatory response. Previously, we published first report sensitized dendritic cell as therapeutic treatment AD BALB/c mice. Our elicited indications that response was not present. This is investigate efficacy safety our prevention transgenic mouse models (PDAPP) AD. We used Immunohistochemistry characterize involvement LXR, ABCA1, CD45 order gain insight into potential mechanisms through which may provide benefit. The indicate (1) use mutant Aβ1-42 durable production, (2) provides significant benefits without global (Th1) inflammation seen prior vaccines, (3) histological studies overall decrease burden, increase CD45, (4) beneficial DC be due LXR/ABCA1 pathway. In future, vaccines could efficacious safe method or circumvents problems associated traditional vaccines.